In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...

Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes with the cell’s normal process of removing faulty or dysfunctional ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

While at SCOPE 2025, Sam Srivastava, CEO at WCG Clinical discusses the challenges and responsibilities of the life sciences industry in building public trust amidst growing anger towards healthcare.

As it did during the COVID-19 pandemic, mRNA technology offers an efficient way forward in developing products for diseases ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...